These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 20448210)

  • 1. Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control.
    Herbert B; Patel D; Waddington SN; Eden ER; McAleenan A; Sun XM; Soutar AK
    Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1333-9. PubMed ID: 20448210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond LDL cholesterol, a new role for PCSK9.
    Akram ON; Bernier A; Petrides F; Wong G; Lambert G
    Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1279-81. PubMed ID: 20554949
    [No Abstract]   [Full Text] [Related]  

  • 3. Low-density lipoprotein receptor activity in Epstein-Barr virus-transformed lymphocytes from heterozygotes for the D374Y mutation in the PCSK9 gene.
    Holla ØL; Cameron J; Berge KE; Kulseth MA; Ranheim T; Leren TP
    Scand J Clin Lab Invest; 2006; 66(4):317-28. PubMed ID: 16777760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant.
    Al-Mashhadi RH; Sørensen CB; Kragh PM; Christoffersen C; Mortensen MB; Tolbod LP; Thim T; Du Y; Li J; Liu Y; Moldt B; Schmidt M; Vajta G; Larsen T; Purup S; Bolund L; Nielsen LB; Callesen H; Falk E; Mikkelsen JG; Bentzon JF
    Sci Transl Med; 2013 Jan; 5(166):166ra1. PubMed ID: 23283366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unexpected roles for PCSK9 in lipid metabolism.
    Soutar AK
    Curr Opin Lipidol; 2011 Jun; 22(3):192-6. PubMed ID: 21494143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.
    Rashid S; Tavori H; Brown PE; Linton MF; He J; Giunzioni I; Fazio S
    Circulation; 2014 Jul; 130(5):431-41. PubMed ID: 25070550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9.
    Humphries SE; Neely RD; Whittall RA; Troutt JS; Konrad RJ; Scartezini M; Li KW; Cooper JA; Acharya J; Neil A
    Clin Chem; 2009 Dec; 55(12):2153-61. PubMed ID: 19797716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK9.
    Roche-Molina M; Sanz-Rosa D; Cruz FM; García-Prieto J; López S; Abia R; Muriana FJ; Fuster V; Ibáñez B; Bernal JA
    Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):50-9. PubMed ID: 25341796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
    Tavori H; Fan D; Blakemore JL; Yancey PG; Ding L; Linton MF; Fazio S
    Circulation; 2013 Jun; 127(24):2403-13. PubMed ID: 23690465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.
    Sun X; Essalmani R; Day R; Khatib AM; Seidah NG; Prat A
    Neoplasia; 2012 Dec; 14(12):1122-31. PubMed ID: 23308045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia.
    Sun XM; Eden ER; Tosi I; Neuwirth CK; Wile D; Naoumova RP; Soutar AK
    Hum Mol Genet; 2005 May; 14(9):1161-9. PubMed ID: 15772090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice.
    Luo Y; Warren L; Xia D; Jensen H; Sand T; Petras S; Qin W; Miller KS; Hawkins J
    J Lipid Res; 2009 Aug; 50(8):1581-8. PubMed ID: 19060325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
    Ason B; van der Hoorn JW; Chan J; Lee E; Pieterman EJ; Nguyen KK; Di M; Shetterly S; Tang J; Yeh WC; Schwarz M; Jukema JW; Scott R; Wasserman SM; Princen HM; Jackson S
    J Lipid Res; 2014 Nov; 55(11):2370-9. PubMed ID: 25258384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice.
    Denis M; Marcinkiewicz J; Zaid A; Gauthier D; Poirier S; Lazure C; Seidah NG; Prat A
    Circulation; 2012 Feb; 125(7):894-901. PubMed ID: 22261195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.
    Benjannet S; Rhainds D; Essalmani R; Mayne J; Wickham L; Jin W; Asselin MC; Hamelin J; Varret M; Allard D; Trillard M; Abifadel M; Tebon A; Attie AD; Rader DJ; Boileau C; Brissette L; Chrétien M; Prat A; Seidah NG
    J Biol Chem; 2004 Nov; 279(47):48865-75. PubMed ID: 15358785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCSK9: a key modulator of cardiovascular health.
    Seidah NG; Awan Z; Chrétien M; Mbikay M
    Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia.
    Maxwell KN; Breslow JL
    Curr Opin Lipidol; 2005 Apr; 16(2):167-72. PubMed ID: 15767856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.
    Awan Z; Baass A; Genest J
    Clin Chem; 2014 Nov; 60(11):1380-9. PubMed ID: 25248569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.
    Ouguerram K; Chetiveaux M; Zair Y; Costet P; Abifadel M; Varret M; Boileau C; Magot T; Krempf M
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1448-53. PubMed ID: 15166014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.